Literature DB >> 836016

Mezlocillin: in vitro studies of a new broad-spectrum penicillin.

G P Bodey, T Pan.   

Abstract

Mezlocillin is a new semisynthetic penicillin that inhibited 71% of the isolates of Serratia marcescens, 67% of Escherichia coli, 50% of Enterobacter spp., and 49% of Klebsiella spp. at a concentration of 12.5 mug/ml. It is also active against both indole-positive and -negative Proteus spp. and gram-positive cocci, except penicillin G-resistant Staphylococcus aureus. At a concentration of 100 mug/ml, it inhibited 94% of the isolates of Pseudomonas aeruginosa. It is more active than ampicillin, carbenicillin, and cephalothin against some gram-negative bacilli.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 836016      PMCID: PMC351920          DOI: 10.1128/AAC.11.1.74

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Proceedings: Causes of death in cancer patients.

Authors:  J Inagaki; V Rodriguez; G P Bodey
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

2.  Infectious complications in renal transplant recipients.

Authors:  T C Eickhoff
Journal:  Transplant Proc       Date:  1973-09       Impact factor: 1.066

3.  Infections in cancer patients. Results with gentamicin sulfate therapy.

Authors:  G P Bodey; E Middleman; T Umsawadi; V Rodriguez
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

4.  In vitro studies of semisynthetic alpha-(substituted-ureido) penicillins.

Authors:  G P Bodey; D Stewart
Journal:  Appl Microbiol       Date:  1971-04
  4 in total
  39 in total

1.  Comparative in vivo activities of cefsulodin, sulbenicillin, and gentamicin against Pseudomonas aeruginosa.

Authors:  M Kondo; K Tsuchiya
Journal:  Antimicrob Agents Chemother       Date:  1978-07       Impact factor: 5.191

2.  Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity.

Authors:  S S Weaver; G P Bodey; B M LeBlanc
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

3.  Clinical evaluation of mezlocillin.

Authors:  H Thadepalli; B Rao
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

4.  Comparison of the activities of the new ureidopenicillins piperacillin, mezlocillin, azlocillin, and Bay k 4999 against gram-negative organisms.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

5.  In vitro activities of ureidopenicillins alone and in combination with amikacin and three cephalosporin antibiotics.

Authors:  J A Moody; L R Peterson; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

6.  Pharmacokinetics of mezlocillin in healthy volunteers.

Authors:  T Bergan
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

7.  PC-904, a new semisynthetic penicillin.

Authors:  G P Bodey; S Weaver; T Pan
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

8.  The pharmacokinetics of furazlocillin in healthy humans.

Authors:  P H Hinderling; U Gundert-Remy; D Förster; W Gau
Journal:  J Pharmacokinet Biopharm       Date:  1983-02

9.  Comparative in vitro study of temocillin (BRL 17421), a new penicillin.

Authors:  R Bolivar; S S Weaver; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

10.  Clinical pharmacology of mezlocillin.

Authors:  B F Issell; G P Bodey; S Weaver
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.